Examining the oleoylethanolamide supplement effects on glycemic status, oxidative stress, inflammation, and anti-mullerian hormone in polycystic ovary syndrome.

What Was Tested

Researchers studied Copper (Supplement) in this randomized controlled trial publication.

This clinical trial was designed and conducted due to the anti-inflammatory potential of Oleoylethanolamide (OEA) to examine the effect of OEA supplement on glycemic status, oxidative stress, inflammatory factors, and anti-Mullerian hormone (AMH) in women with polycystic ovary syndrome (PCOS).

Why It Was Studied

This study was retrospectively (09-01-2022) registered in the Iranian website ( www.irct.ir ) for registration of clinical trials (IRCT20141025019669N20).

Who Took Part

The abstract describes 90 women taking part.

The age groups tagged for this paper are young adults and adults, women only.

This study was a randomized clinical trial, double-blinded, placebo-controlled that was carried out on 90 women with PCOS.

Patients were divided into two groups: receiving an OEA supplement (n = 45) or a placebo (n = 45).

How the Study Was Run

The researchers set it up as a randomized, double-blind and placebo-controlled study.

The women were allocated by chance, so the Copper (Supplement) group and the comparison group should start out alike.

Neither the women nor the staff measuring them knew who was on Copper (Supplement), so expectations could not easily colour the readings.

The comparison arm used a placebo, so changes seen with Copper (Supplement) could be set against what happens without it.

Demographic data were collected through questionnaires.

Fasting blood sugar (FBS), insulin resistance (IR), total antioxidant capacity (TAC), malondialdehyde (MDA), C-reactive protein (CRP), tumor necrosis factor-alpha (TNF-α), and AMH were measured before and after the study.

What Was Measured

The subject headings attached to it are Polycystic Ovary Syndrome, Endocannabinoids, Oxidative Stress, Oleic Acids, Inflammation, Dietary Supplements and Blood Glucose.

The authors tagged it with the keywords Anti-mullerian hormone, Glycemic status and Oleoylethanolamide.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Copper (Supplement) in 90 women.

Its findings take up roughly 4 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2024 (Journal of ovarian research), a journal based in England.

More context: the Copper (Supplement) compound page, all human trials.